Hennion & Walsh Asset Management Inc. Buys 27,598 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Hennion & Walsh Asset Management Inc. increased its position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 125.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 49,608 shares of the company's stock after purchasing an additional 27,598 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.10% of Immunocore worth $1,463,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Exchange Traded Concepts LLC raised its holdings in Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock worth $158,000 after acquiring an additional 1,461 shares during the last quarter. Connective Portfolio Management LLC bought a new position in Immunocore during the third quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. raised its position in shares of Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock valued at $231,000 after buying an additional 3,053 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Immunocore during the 2nd quarter valued at approximately $303,000. Finally, Seven Eight Capital LP bought a new position in Immunocore during the 2nd quarter valued at about $434,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Price Performance

Shares of Immunocore stock traded down $0.08 during trading on Friday, hitting $29.02. The stock had a trading volume of 152,291 shares, compared to its average volume of 306,079. The firm has a market cap of $1.45 billion, a P/E ratio of -30.55 and a beta of 0.76. Immunocore Holdings plc has a fifty-two week low of $27.69 and a fifty-two week high of $76.98. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The business has a fifty day moving average of $30.75 and a two-hundred day moving average of $33.57.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $80.25 million for the quarter, compared to analysts' expectations of $78.94 million. During the same period in the previous year, the company posted ($0.59) EPS. Immunocore's revenue was up 23.7% on a year-over-year basis. On average, sell-side analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on IMCR shares. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a report on Friday, January 10th. Mizuho cut shares of Immunocore from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $72.00 to $38.00 in a research note on Monday, November 11th. UBS Group assumed coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a "sell" rating and a $24.00 price objective for the company. Finally, Guggenheim cut shares of Immunocore from a "buy" rating to a "neutral" rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Immunocore currently has an average rating of "Moderate Buy" and a consensus target price of $65.64.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.